To investigate whether a positive synergy between lymphangiogenesis and cancer immunotherapy could be leveraged in a cancer vaccine, lethally irradiated tumor cells overexpressing VEGF-C, along with topical adjuvants, were used. Here, VEGFC is linked to neoplasm.